Briacell Therapeutics Corp (BCTX) has a current Price-to-Book (P/B) ratio of 1.35. Compared to its 3-year average P/B ratio of -6.84, the current P/B ratio is approximately -119.78% higher. Relative to its 5-year average P/B ratio of 0.61, the current P/B ratio is about 120.89% higher. Briacell Therapeutics Corp (BCTX) has a Forward Free Cash Flow (FCF) yield of approximately -214.68%. Compared to its 3-year average FCF yield of -102.45%, the current FCF yield is approximately 109.55% lower. Relative to its 5-year average FCF yield of -64.31%, the current FCF yield is about 233.81% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BCTX competitors is 1.07, providing a benchmark for relative valuation. Briacell Therapeutics Corp Corp (BCTX.O) exhibits a P/S ratio of 6.41, which is 500% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BCTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BCTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BCTX currently overvalued or undervalued?

What is Briacell Therapeutics Corp (BCTX) fair value?

BCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Briacell Therapeutics Corp (BCTX) is between 0.27 to 4.59 according to relative valuation method.

How does BCTX's valuation metrics compare to the industry average?

The average P/S ratio for BCTX's competitors is 1.07, providing a benchmark for relative valuation. Briacell Therapeutics Corp Corp (BCTX) exhibits a P/S ratio of 6.41, which is 500.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Briacell Therapeutics Corp (BCTX) as of Mar 03 2026?

As of Mar 03 2026, Briacell Therapeutics Corp (BCTX) has a P/B ratio of 1.35. This indicates that the market values BCTX at 1.35 times its book value.

What is the current FCF Yield for Briacell Therapeutics Corp (BCTX) as of Mar 03 2026?

As of Mar 03 2026, Briacell Therapeutics Corp (BCTX) has a FCF Yield of -214.68%. This means that for every dollar of Briacell Therapeutics Corp's market capitalization, the company generates -214.68 cents in free cash flow.

What is the current Forward P/E ratio for Briacell Therapeutics Corp (BCTX) as of Mar 03 2026?

As of Mar 03 2026, Briacell Therapeutics Corp (BCTX) has a Forward P/E ratio of -0.63. This means the market is willing to pay $-0.63 for every dollar of Briacell Therapeutics Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Briacell Therapeutics Corp (BCTX) as of Mar 03 2026?

As of Mar 03 2026, Briacell Therapeutics Corp (BCTX) has a Forward P/S ratio of 6.41. This means the market is valuing BCTX at $6.41 for every dollar of expected revenue over the next 12 months.

BCTX Valuation